BioCryst Pharmaceuticals(BCRX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - BioCryst Pharmaceuticals reported full-year ORLADEYO revenue of $601.8 million, representing a 38% increase year-on-year and a 43% increase when excluding the European business sold in October [5][20] - Non-GAAP total revenue increased by 45% year-on-year, with non-GAAP ORLADEYO revenues rising by approximately $169 million or 43% year-on-year [20][21] - Non-GAAP operating profit surged to $214 million, marking a 198% increase year-on-year, the highest in the company's history [21][24] Business Line Data and Key Metrics Changes - The HAE portfolio saw significant growth, with ORLADEYO capsules for ages 12 and up and ORLADEYO Pellets for younger children being key products [7][9] - The pivotal trial for navenibart is progressing well, with a mean attack rate reduction of 92% for every three months dosing and 90% for every six months dosing reported [14][15] Market Data and Key Metrics Changes - The company anticipates full-year 2026 ORLADEYO revenues to be between $625 million and $645 million, representing approximately 13% growth over 2025 revenues adjusted for Europe [24][25] - The pediatric market for ORLADEYO is expected to grow significantly, with the potential to double the number of diagnosed children and treatment rates [77] Company Strategy and Development Direction - BioCryst aims to remain a profitable rare disease company focused on commercialization, innovation, and disciplined clinical development [5][6] - The company is committed to capital allocation that drives long-term value creation and plans to terminate programs lacking a compelling path forward [22][24] - The strategy includes maintaining a strong focus on the HAE market, with a portfolio of differentiated products to meet diverse patient needs [6][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve blockbuster potential for ORLADEYO and highlighted the importance of patient growth and market dynamics [25][26] - The company is optimistic about the launch of ORLADEYO Pellets for children and the ongoing development of navenibart and BCX-17725 [12][89] Other Important Information - The company ended the year with a strong liquidity position of $337.5 million in cash and investments [24] - BioCryst entered into a $400 million financing facility with Blackstone Life Sciences to support growth initiatives [24] Q&A Session Summary Question: Timing for navenibart regulatory submission - Management confirmed that everything is on track for filing by the end of next year, with approval expected by late 2028 [31][33] Question: Predicting super responders for ORLADEYO - There is no way to predict super responders; patients must try the medication to determine their response [37][39] Question: Impact of new entrants on ORLADEYO - Management noted that new entrants are not expected to impact ORLADEYO negatively, as patients prefer oral prophylaxis over injectables [70][71] Question: ORLADEYO price increase and growth levers - A 9% price increase was implemented, with a focus on net patient growth as the primary KPI for achieving long-term revenue goals [75][76] Question: Netherton syndrome trial data release - Management plans to release data from both parts 3 and 4 of the Netherton syndrome trial together [57][58]